Nurix’s therapies control E3 ubiquitin ligases, the key enzymes responsible for protein breakdown within the natural cellular process. By controlling protein levels, our platforms can be leveraged to treat many different diseases. Currently, we are focused on developing drugs for treatments for cancer including novel, small molecule immuno-oncology agents.
Nurix was founded in 2009 by a team of internationally renowned scientific experts in the E3 ubiquitin ligase regulation and structure field. Since incorporation, the company has built a seasoned team of leaders with wide-ranging backgrounds in small molecule drug development. Nurix is funded by leading life sciences investors, Third Rock Ventures and The Column Group, and is headquartered in San Francisco, California.
Founders »Management Team »Board of Directors »